Hayfield, PA, United States of America

Corin Dorfmeier

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Novartis Ag, University of Pennsylvania. Active years: 2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Corin Dorfmeier. Retrieved from https://idiyas.com/inventor/corin-dorfmeier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Corin Dorfmeier: Innovator in Cancer Biomarkers

Introduction

Corin Dorfmeier is a notable inventor based in Hayfield, Pennsylvania. He has made significant contributions to the field of cancer research, particularly in the development of biomarkers that predict therapeutic responsiveness to chimeric antigen receptor therapy.

Latest Patents

Dorfmeier holds a patent for "Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof." This patent discloses cancer biomarkers and methods of using them, which have the potential to enhance treatment outcomes for patients undergoing CAR therapy.

Career Highlights

Throughout his career, Dorfmeier has worked with prominent organizations, including Novartis AG and the University of Pennsylvania. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Dorfmeier has collaborated with notable colleagues such as Felipe Bedoya and Hans Bitter. These partnerships have furthered his research and innovation in cancer biomarkers.

Conclusion

Corin Dorfmeier's work in cancer biomarkers exemplifies the impact of innovative research on therapeutic advancements. His contributions are paving the way for improved cancer treatment strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…